Seki Morinobu, Kawata Yayoi, Hayashi Ayako, Fujimoto Shinji
Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
Parkinson's Disease Center, Keio University Hospital, Tokyo, Japan.
Front Neurol. 2025 Jul 4;16:1571718. doi: 10.3389/fneur.2025.1571718. eCollection 2025.
Parkinson's disease (PD) is a neurodegenerative disorder, with increasing prevalence among aging populations. Gender differences in PD extend to symptom presentation and treatment response, suggesting the need for gender-specific management strategies.
This gender-stratified analysis of a retrospective observational study used data from three nationwide Japanese healthcare databases. Patients aged ≥30 years diagnosed with PD between June 2016 and May 2021 were included. Patient demographics, prescribing patterns, and levodopa dosages were analyzed descriptively.
Of 39,731 patients with PD identified, females ( = 22,724) outnumbered males ( = 17,007), especially in the ≥75 years group. Levodopa was the most commonly prescribed drug for both genders. The mean ± standard deviation maximum levodopa dose was numerically higher in males (520.0 ± 426.8 mg) compared with females (498.7 ± 424.2 mg). Usage of monoamine oxidase B inhibitors (MAOBI) was 24.0% in males and 18.9% in females. Among newly treated patients, >70% of both genders started treatment with levodopa monotherapy; a slightly higher proportion of males tended toward levodopa combination therapy. For both genders, concomitant drugs were most commonly MAOBI, non-ergot dopamine agonist, and zonisamide. However, females tended to receive a more diverse range of medications than these three drugs.
This analysis highlights the high number of elderly female patients with PD in Japan. Slight gender differences in maximum levodopa dose and prescriptions for anti-PD drugs were observed. These findings emphasize the importance of personalized treatment approaches in PD management considering gender-specific differences in drug efficacy and side effects.
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053425, identifier UMIN000046823.
帕金森病（PD）是一种神经退行性疾病，在老年人群中的患病率不断上升。PD的性别差异延伸至症状表现和治疗反应，这表明需要针对性别的管理策略。
这项对一项回顾性观察性研究的性别分层分析使用了来自日本三个全国性医疗保健数据库的数据。纳入了2016年6月至2021年5月期间诊断为PD的年龄≥30岁的患者。对患者人口统计学、处方模式和左旋多巴剂量进行了描述性分析。
在确定的39731例PD患者中，女性（n = 22724）多于男性（n = 17007），尤其是在≥75岁年龄组。左旋多巴是两性最常用的药物。男性的平均±标准差最大左旋多巴剂量（520.0±426.8毫克）在数值上高于女性（498.7±424.2毫克）。单胺氧化酶B抑制剂（MAOBI）的使用率男性为24.0%，女性为18.9%。在新治疗的患者中，超过70%的两性患者开始使用左旋多巴单药治疗；男性倾向于左旋多巴联合治疗的比例略高。对于两性来说，伴随药物最常见的是MAOBI、非麦角多巴胺激动剂和唑尼沙胺。然而，女性倾向于接受比这三种药物更多样化的药物。
该分析突出了日本老年女性PD患者数量众多的情况。观察到最大左旋多巴剂量和抗PD药物处方存在轻微的性别差异。这些发现强调了在PD管理中考虑药物疗效和副作用的性别差异采取个性化治疗方法的重要性。
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053425，标识符UMIN000046823。
